Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.

Vineeta ShobhaChandrashekara SrikantiahVijay RaoAnu DesaiRamesh JoisBalebail G DharmanandSharath KumarPradeep KumarChethana DharmapalaiahKurugodu Mathada MahendranathShiva PrasadManisha Ashwin DawareYogesh SinghUma KarjigiS NagarajK R Anupama

Published in: International journal of rheumatic diseases (2018)

Close monitoring of patients receiving biologics is essential for early identification of adverse events, especially in test negative patients. Prophylaxis can effectively reduce the risk of developing TB in patients positive for screening.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
mycobacterium tuberculosis
multiple sclerosis
human immunodeficiency virus
patient reported
pulmonary tuberculosis
electronic health record